The global Rescue Inhaler Market is estimated to be valued at US$ 15.54 Bn in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:-
Rescue inhalers provide rapid relief from symptoms caused by asthma attacks and chronic obstructive pulmonary disease (COPD) flare-ups. Popular rescue inhalers contain medications such as albuterol and levalbuterol that work by relaxing airway muscles to widen the airways and make breathing easier. They provide quick symptom relief and are prescribed to adults and children with asthma or COPD for emergency use during flare ups. The rising prevalence of chronic respiratory diseases globally has created significant demand for rescue inhalers.
Market key trends:-
One of the major trends in the rescue inhaler market is the introduction of generic versions of branded drugs. The patent expiry of blockbuster drugs such as albuterol has encouraged many pharmaceutical companies to launch low-cost generic rescue inhalers. This has significantly reduced treatment costs and improved accessibility for patients. Another key trend is the growing preference for combination rescue inhalers that provide both rapid and long-acting symptom relief. Companies are innovating novel formulations that integrate bronchodilators with corticosteroids to prevent future exacerbations. Furthermore, the development of compact, easy-to-use devices is enhancing patient convenience and compliance.
Porter’s Analysis:-
- Threat of new entrants: The threat of new entrants is moderate. While establishing manufacturing facilities and gaining brand recognition requires significant investments, the market is growing at a fast pace which could attract new players.
- Bargaining power of buyers: The bargaining power of buyers is high given the availability of generic alternatives. Buyers can choose from multiple branded and generic products easily.
- Bargaining power of suppliers: The bargaining power of suppliers is moderate since raw material inputs are commoditized and suppliers do not have much control over prices. However, the industry depends on a few major API suppliers.
- Threat of new substitutes: The threat of substitutes is low as there are limited treatment options for respiratory illnesses currently.
- Competitive rivalry: High due to presence of many global players actively competing on basis of strong brand recognition, product differentiation and pricing.
Key Takeaways:-
The global Rescue Inhaler Market Demand is expected to witness high growth, exhibiting CAGR of 8.7% over the forecast period, due to increasing prevalence of respiratory diseases like asthma and COPD.
Regional analysis: North America holds the largest share in the rescue inhaler market owing to growing geriatric population and increased adoption of new therapies. Asia Pacific is expected to witness the fastest growth over the forecast period with growing medical infrastructure and awareness.
Key players operating in the rescue inhaler market are GlaxoSmithKline, Teva Pharmaceuticals, AstraZeneca , Boehringer Ingelheim, Merck, Novartis, Pfizer, Sunovion Pharmaceuticals, Roche, 3M, Omron Healthcare, Philips. Key players are focusing on new product developments and launches to strengthen their market shares. For instance, GSK launched an enhanced Ellipta portfolio including Trelegy Ellipta for COPD and Nucala for severe eosinophilic asthma.
Read More - https://www.trendingwebwire.com/rescue-inhaler-market-size-and-demand-analysis/
